• Xi He, Shuo Quan, Min Xu, Silveria Rodriguez, Shih Lin Goh, Jiajie Wei, Arthur Fridman, Kenneth A Koeplinger, Steve S Carroll, Jay A Grobler, Amy S Espeseth, David B Olsen, Daria J Hazuda, and Dai Wang.
• Infectious Disease and Vaccines, Merck and Company, Inc., Kenilworth, NJ 07033.
• Proc. Natl. Acad. Sci. U.S.A. 2021 Apr 13; 118 (15).

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) research and antiviral discovery are hampered by the lack of a cell-based virus replication system that can be readily adopted without biosafety level 3 (BSL-3) restrictions. Here, the construction of a noninfectious SARS-CoV-2 reporter replicon and its application in deciphering viral replication mechanisms and evaluating SARS-CoV-2 inhibitors are presented. The replicon genome is replication competent but does not produce progeny virions. Its replication can be inhibited by RdRp mutations or by known SARS-CoV-2 antiviral compounds. Using this system, a high-throughput antiviral assay has also been developed. Significant differences in potencies of several SARS-CoV-2 inhibitors in different cell lines were observed, which highlight the challenges of discovering antivirals capable of inhibiting viral replication in vivo and the importance of testing compounds in multiple cell culture models. The generation of a SARS-CoV-2 replicon provides a powerful platform to expand the global research effort to combat COVID-19.Copyright © 2021 the Author(s). Published by PNAS.

23 keywords...

hide…